Onset of efficacy and adverse events during Cenobamate titration period

OBJECTIVES: Cenobamate is an antiseizure medication (ASM) approved in Europe as adjunctive therapy for adults with inadequately controlled focal seizures. This post hoc analysis reports onset of efficacy and characterizes time to onset, duration, and severity of the most common treatment‐emergent ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Steinhoff, Bernhard J., Ben‐Menachem, Elinor, Brandt, Christian, García Morales, Irene, Rosenfeld, William E., Santamarina, Estevo, Serratosa, José M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545218/
https://www.ncbi.nlm.nih.gov/pubmed/35711112
http://dx.doi.org/10.1111/ane.13659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545218/
https://www.ncbi.nlm.nih.gov/pubmed/35711112
http://dx.doi.org/10.1111/ane.13659

Ejemplares similares